Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Mu-opioid Receptor Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Mu-opioid Receptor Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023
The µ-opioid receptor (Mu opioid receptor- MOR) is an inhibitory G-protein coupled receptor, which activates the G1 alpha subunit, inhibiting adenylate cyclase activity, and lowering cAMP levels. These classes of opioid receptors have a high affinity for enkephalins and beta-endorphin. The µ-opioid receptor induces acute changes in neuronal excitability by suppressing the presynaptic release of GABA. Activation of the µ-opioid receptor by an agonist causes analgesia, sedation, nausea, euphoria, respiratory depression, miosis, and others. µ-opioid agonists are primarily used for the management of moderate to severe pain, chronic pain, post-operative pain, pain induced by cancer, and others. Takeda Pharmaceutical, Tris Pharm, AbbVie, Assertio Therapeutics, Gilead Sciences, and Ensysce Biosciences are some of the major market players in the mu-opioid agonists market, Moreover, there are drug molecules under the pipeline of various companies for other disease conditions.
Key Market Developments:
Approved Drug Molecules and Brand Names for Mu-opioid Receptor Agonists:
Drugs under the Pipeline for µ-Opioid Agonists:
Clinical Activity and Developments of Mu-opioid Receptor Agonists:
Currently, there are 62 products in the opioid mu receptor agonists, including more than 30 approved drugs in the market, and the rest of the drug molecules are in the clinical development phases.
|
Molecule Name |
Number of Studies |
|
Cebranopadol (TRN-228) |
15 |
|
AeroLEF (Fentanyl) |
7 |
|
Oxycodone ER (PF614) |
5 |
|
SHR8554 |
5 |
|
Loxicodegol (NKTR-181) |
4 |
|
TRV734 |
4 |
|
Methionine Enkephalin (STAT-401) |
3 |
|
nebulized Fentanyl citrate |
3 |
|
Oxycodone ER (Egalet-002) |
3 |
|
Staccato Fentanyl (AZ-003) |
3 |
|
Tramadol (AVE-901) |
2 |
|
Arymo (Morphine) |
2 |
|
E-58425 |
2 |
|
JI-101 |
2 |
|
LY03014 |
2 |
|
TussiCaps (Hydrocodone/Chlorpheniramine) |
2 |
|
Celecoxib/Tramadol (YYC301) |
2 |
|
Etoricoxib/Tramadol |
2 |
|
Imrecoxib/Tramadol (HR18042) |
2 |
|
CEP-37440 |
2 |
|
ETR028 |
1 |
|
ETR029 |
1 |
|
Fentanyl Ethypharm (Fentanyl citrate) |
1 |
|
MEB-1170 |
1 |
|
ORP-101 |
1 |
|
Viotra (Tramadol ER) |
1 |
|
deuterated Mitragynine (KUR-101) |
1 |
|
Hydromorphone once daily (CEP-33236) |
1 |
The µ-opioid agonists such as morphine, methadone, tramadol, oxycodone, and others are primarily used in the treatment of cancer pain, opioid-related disorders, postoperative pain, and acute pain. Drug molecules like cebranopadol are in the clinical phase-III for acute pain and back pain, and in phase-II for cancer pain and neuropathic pain. Methionine Enkephalin is in phase-II for HIV infections, liver cancer, ovarian cancer, and pancreatic cancer. Celecoxib/tramadol combination drug is in phase-III for osteoarthritis. OrphoMed’s ORP-101, a buprenorphine dimer is in phase-II for irritable bowel syndrome.
Collegium Pharmaceuticals’s Xtampza and Nucynta ER had total sales of US$ 1,38,804 million, and 1,12,058 million respectively in 2022. Mallinckrodt Pharmaceuticals’s Xartemis XR will see all of its patent expiration by 2032. According to a report, consumption of Morphine in the year 2021 was the highest in Europe (39.4%), followed by the USA (33.4%), Australia and New Zealand (7.9%), Canada (4.5%), Japan (0.5%), and others (14.3%). According to World Drug Report 2019, about 9.3 million people in the USA misused pharmaceutical opioids which included hydrocodone (5.1 million people), oxycodone (3.2 million), and fentanyl products (0.26 million).
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Morphine sulfate, Methadone, Tramadol hydrochloride, Oxycodone controlled release, Loperamide are the few approved µ-Opioid agonists in the market.
Takeda Pharmaceutical, Tris Pharm, AbbVie, Assertio Therapeutics, Gilead Sciences, and Ensysce Biosciences are the major market players in the µ-Opioid agonists.
Major indications for µ-Opioid agonists are cancer pain, opioid-related disorders, postoperative pain, and acute pain.
There are more than 30 molecules in clinical development for µ-Opioid agonists.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.